ClearPoint Neuro (CLPT) Projected to Release Quarterly Earnings on Monday

ClearPoint Neuro (NASDAQ:CLPT) will likely be announcing its Q2 2026 results after the market closes on Monday, August 3rd. Analysts expect ClearPoint Neuro to post earnings of ($0.27) per share and revenue of $12.7330 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Monday, August 3, 2026 at 4:30 PM ET.

ClearPoint Neuro (NASDAQ:CLPT) last released its earnings results on Wednesday, May 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.04). ClearPoint Neuro had a negative return on equity of 140.96% and a negative net margin of 71.57%.The company had revenue of $12.13 million during the quarter, compared to analyst estimates of $11.97 million. On average, analysts expect ClearPoint Neuro to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ClearPoint Neuro Price Performance

ClearPoint Neuro stock opened at $14.12 on Monday. The company has a debt-to-equity ratio of 2.63, a quick ratio of 4.88 and a current ratio of 5.79. The company has a market cap of $423.46 million, a price-to-earnings ratio of -13.98 and a beta of 1.23. ClearPoint Neuro has a 1 year low of $8.27 and a 1 year high of $30.10. The firm has a 50 day moving average price of $15.06 and a 200 day moving average price of $13.08.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. B. Riley Financial boosted their price objective on shares of ClearPoint Neuro from $20.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ClearPoint Neuro in a research report on Friday, July 17th. Finally, Stifel Nicolaus set a $16.00 target price on ClearPoint Neuro in a report on Tuesday, June 9th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $23.00.

Insider Buying and Selling

In other news, CEO Joseph Burnett sold 60,000 shares of the stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $17.79, for a total value of $1,067,400.00. Following the completion of the sale, the chief executive officer owned 116,842 shares in the company, valued at approximately $2,078,619.18. This trade represents a 33.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Timothy T. Richards sold 5,415 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $12.17, for a total value of $65,900.55. Following the transaction, the director directly owned 87,198 shares in the company, valued at $1,061,199.66. This trade represents a 5.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 108,349 shares of company stock worth $1,796,118. Company insiders own 6.94% of the company’s stock.

Institutional Trading of ClearPoint Neuro

A number of hedge funds have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd purchased a new position in shares of ClearPoint Neuro in the fourth quarter valued at $25,000. BNP Paribas Financial Markets grew its holdings in ClearPoint Neuro by 2,435.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company’s stock valued at $27,000 after purchasing an additional 2,143 shares in the last quarter. Russell Investments Group Ltd. increased its stake in ClearPoint Neuro by 1,079.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 2,358 shares of the company’s stock worth $51,000 after buying an additional 2,158 shares during the period. Legal & General Group Plc purchased a new stake in ClearPoint Neuro during the 2nd quarter worth $35,000. Finally, Raymond James Financial Inc. acquired a new position in ClearPoint Neuro in the 2nd quarter worth $80,000. Hedge funds and other institutional investors own 30.08% of the company’s stock.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.